Larrubia Marfil, Juan Ramon's dataset comprises a multicentre cohort of 1,556 chronic hepatitis C patients with sustained virologic response after direct-acting antiviral treatment. The data includes follow-up for a median of 74 months, tracking hepatocellular carcinoma development, metformin treatment, and confounders like FIB-4, cirrhosis, and diabetes. It was harvested from e-cienciaDatos and last updated in October 2025.
Use Cases
- Assessing hepatocellular carcinoma incidence risk based on FIB-4 levels as described in the study.
- Evaluating the protective association of metformin use against HCC development in high-risk patients.
- Conducting survival analysis using Cox models and Random Survival Forest methods as referenced in the description.
- Stratifying HCC risk by factors like clinically significant portal hypertension and type 2 diabetes mellitus mentioned in the results.
Strengths
- Includes 1,556 patient records from a multicentre cohort.
- Provides a median follow-up period of 74 months for longitudinal analysis.
- Contains key clinical variables like FIB-4, metformin use, cirrhosis, and HCC outcome as detailed in the study.
Limitations
- Column-level documentation is absent; field semantics must be inferred after download.
- Row count is unknown, which may limit suitability assessment.
- Description metadata is limited; actual data quality requires manual inspection after download.
Provenance
- Source
- e-cienciaDatos Harvested Dataverse
- Collection Method
- Retrospective analysis of prospectively collected data from a multicentre cohort.
- Time Range
- Follow-up period with a median of 74 months.
- Freshness
- Last updated 2025-10-14 21:52:06; freshness should be verified.
- Geography
- null